Drug Profile


Alternative Names: BBR 3438

Latest Information Update: 18 Nov 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novuspharma; University of Vermont
  • Developer Novuspharma
  • Class Anthraquinones; Antineoplastics; Pyrazolones; Small molecules
  • Mechanism of Action DNA inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Gastric cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 18 Nov 2002 Discontinued - Phase-II for Gastric cancer in Europe (IV)
  • 18 Nov 2002 Discontinued - Phase-II for Gastric cancer in Germany (unspecified route)
  • 18 Nov 2002 Discontinued - Phase-II for Ovarian cancer in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top